age-related macular degeneration (AMD)

IOL selection important in patients with retinal diseaseWhen dealing with patients with retinal disease, macular disease, or a meaningful risk of retinal detachment, certain types of IOLs should be avoided due to potential complications.
ARVO 2017 showcases vision research advancesAdvances in presbyopia, dry eye and allergy, and age-related macular degeneration filled this year’s meeting of the Association for Research in Vision and Ophthalmology.
5-year CATT analysis finds anti-VEGF drugs a long-term AMD therapyAfter 5 years of follow-up in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), the visual acuity gains achieved during the first 2 years of anti-VEGF treatment were not maintained, the choroidal neovascular lesions continued to evolve with evidence of persistent activity in some eyes, and there was increased retinal thinning and geographic atrophy (GA).
Anti-PDGF inhibitor development continues despite negative resultsDespite the failure of 2 clinical trials involving a combination therapy of platelet-derived growth factor (PDGF) inhibitor and anti-vascular endothelial growth factor (anti-VEGF) therapy, a third phase III study continues.
How zinc affects AMDOne of the greatest ongoing food fights in eye care concerns the role of antioxidants and zinc in age-related macular degeneration (AMD) prevention and the movement of genetic testing from the theoretical research lab to applied science.
DARPin molecule prolongs anti-VEGF activity in nAMDA phase III study program investigating abicipar pegol (Allergan) for the treatment of neovascular age-related macular degeneration (nAMD) is underway based on promising efficacy and safety results in phase II studies.
No one imaging tool fits all in identifying AMD lesionsMultimodal imaging, including traditional and newer techniques, is necessary for identifying the spectrum of retinal lesions associated with age-related macular degeneration (AMD), said David Sarraf, MD.
Retina surgeon’s AMD regimen at center of Medicare fraud case
Retina surgeon’s AMD regimen at center of Medicare fraud caseEarlier this month, a jury convicted West Palm Beach retina surgeon Solomon Melgen, MD, on 67 counts of Medicare fraud. This high-profile case hit very close to home, as myself and another retina specialist from my own community were on opposing sides of the case.
NRTIs hold promise for preventing or treating AMDNucleoside-reverse, transcriptase inhibitors (NRTIs) or their derivatives could one day be used to prevent or treat age-related macular degeneration (AMD), according to Jayakrishna Ambati, MD.
Multiple strategies pursue treatment of dry AMDThere are a number of ongoing clinical trials investigating treatments for dry age-related macular degeneration (AMD). These modalities include medications that are already in use for other indications and investigational agents representing various novel mechanisms of action.